Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Watson Acquires Andrx Despite OAI Hold Status

This article was originally published in The Pink Sheet Daily

Executive Summary

The $1.9 bil. acquisition will create the third largest generic pharmaceutical company in the U.S, Watson said March 13.

You may also be interested in...



Watson Integration Of Andrx Underway With 66 Combined ANDAs Pending

With acquisition of Andrx finalized, Watson now has three business divisions: Brand, Generic and Anda distribution.

Watson Integration Of Andrx Underway With 66 Combined ANDAs Pending

With acquisition of Andrx finalized, Watson now has three business divisions: Brand, Generic and Anda distribution.

Watson Looks To Counter Generic Pressures Through Products With High Barrier To Entry

Drug maker says it is on track to recruit a generic division president by the end of September.

Related Content

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel